127 related articles for article (PubMed ID: 35802677)
1. DNA Methylation Profiling Identifies Subgroups of Lung Adenocarcinoma with Distinct Immune Cell Composition, DNA Methylation Age, and Clinical Outcome.
Guidry K; Vasudevaraja V; Labbe K; Mohamed H; Serrano J; Guidry BW; DeLorenzo M; Zhang H; Deng J; Sahu S; Almonte C; Moreira AL; Tsirigos A; Papagiannakopoulos T; Pass H; Snuderl M; Wong KK
Clin Cancer Res; 2022 Sep; 28(17):3824-3835. PubMed ID: 35802677
[TBL] [Abstract][Full Text] [Related]
2. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.
Kadara H; Choi M; Zhang J; Parra ER; Rodriguez-Canales J; Gaffney SG; Zhao Z; Behrens C; Fujimoto J; Chow C; Yoo Y; Kalhor N; Moran C; Rimm D; Swisher S; Gibbons DL; Heymach J; Kaftan E; Townsend JP; Lynch TJ; Schlessinger J; Lee J; Lifton RP; Wistuba II; Herbst RS
Ann Oncol; 2017 Jan; 28(1):75-82. PubMed ID: 27687306
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide DNA methylation analysis of lung carcinoma reveals one neuroendocrine and four adenocarcinoma epitypes associated with patient outcome.
Karlsson A; Jönsson M; Lauss M; Brunnström H; Jönsson P; Borg Å; Jönsson G; Ringnér M; Planck M; Staaf J
Clin Cancer Res; 2014 Dec; 20(23):6127-40. PubMed ID: 25278450
[TBL] [Abstract][Full Text] [Related]
4. Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study.
Shi J; Hua X; Zhu B; Ravichandran S; Wang M; Nguyen C; Brodie SA; Palleschi A; Alloisio M; Pariscenti G; Jones K; Zhou W; Bouk AJ; Boland J; Hicks B; Risch A; Bennett H; Luke BT; Song L; Duan J; Liu P; Kohno T; Chen Q; Meerzaman D; Marconett C; Laird-Offringa I; Mills I; Caporaso NE; Gail MH; Pesatori AC; Consonni D; Bertazzi PA; Chanock SJ; Landi MT
PLoS Med; 2016 Dec; 13(12):e1002162. PubMed ID: 27923066
[TBL] [Abstract][Full Text] [Related]
5. Genomic Profiling of Lung Adenocarcinoma in Never-Smokers.
Devarakonda S; Li Y; Martins Rodrigues F; Sankararaman S; Kadara H; Goparaju C; Lanc I; Pepin K; Waqar SN; Morgensztern D; Ward J; Masood A; Fulton R; Fulton L; Gillette MA; Satpathy S; Carr SA; Wistuba I; Pass H; Wilson RK; Ding L; Govindan R
J Clin Oncol; 2021 Nov; 39(33):3747-3758. PubMed ID: 34591593
[TBL] [Abstract][Full Text] [Related]
6. Identification of Prognostic DNA Methylation Signatures in Lung Adenocarcinoma.
Wang P; Xu G; Gao E; Xu Y; Liang L; Jiang G; Duan L
Oxid Med Cell Longev; 2022; 2022():8802303. PubMed ID: 35814273
[TBL] [Abstract][Full Text] [Related]
7. DNA methylation-based lung adenocarcinoma subtypes can predict prognosis, recurrence, and immunotherapeutic implications.
Xu F; He L; Zhan X; Chen J; Xu H; Huang X; Li Y; Zheng X; Lin L; Chen Y
Aging (Albany NY); 2020 Nov; 12(24):25275-25293. PubMed ID: 33234739
[TBL] [Abstract][Full Text] [Related]
8. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide analysis of the hypoxia-related DNA methylation-driven genes in lung adenocarcinoma progression.
Li H; Tong L; Tao H; Liu Z
Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32031203
[TBL] [Abstract][Full Text] [Related]
10. Identification of a methylomics-associated nomogram for predicting overall survival of stage I-II lung adenocarcinoma.
Wang H; Wei C; Pan P; Yuan F; Cheng J
Sci Rep; 2021 May; 11(1):9938. PubMed ID: 33976305
[TBL] [Abstract][Full Text] [Related]
11. Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment.
Akhave N; Zhang J; Bayley E; Frank M; Chiou SH; Behrens C; Chen R; Hu X; Parra ER; Lee WC; Swisher S; Solis L; Weissferdt A; Moran C; Kalhor N; Zhang J; Scheet P; Vaporciyan AA; Sepesi B; Gibbons DL; Heymach JV; Lee JJ; Wistuba II; Andrew Futreal P; Zhang J; Fujimoto J; Reuben A
Lung Cancer; 2022 Oct; 172():19-28. PubMed ID: 35973335
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral immunoglobulin isotypes predict survival in lung adenocarcinoma subtypes.
Isaeva OI; Sharonov GV; Serebrovskaya EO; Turchaninova MA; Zaretsky AR; Shugay M; Chudakov DM
J Immunother Cancer; 2019 Oct; 7(1):279. PubMed ID: 31665076
[TBL] [Abstract][Full Text] [Related]
13. [Comprehensive Analysis of the Relationship between m6A Methylation Patterns and Immune Microenvironment in Lung Adenocarcinoma].
Ke J; Cui J; Yang X; Du X; Ma B; Yu L
Zhongguo Fei Ai Za Zhi; 2022 May; 25(5):311-322. PubMed ID: 35599007
[TBL] [Abstract][Full Text] [Related]
14. Increased Tumor Intrinsic Growth Potential and Decreased Immune Function Orchestrate the Progression of Lung Adenocarcinoma.
Zhao Y; Shang J; Gao J; Han H; Gao Z; Yan Y; Zheng Q; Ye T; Fu F; Deng C; Ma Z; Zhang Y; Zheng D; Zheng S; Li Y; Cao Z; Shi L; Chen H
Front Immunol; 2022; 13():921761. PubMed ID: 35844495
[TBL] [Abstract][Full Text] [Related]
15. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
Front Immunol; 2021; 12():723172. PubMed ID: 34539658
[TBL] [Abstract][Full Text] [Related]
16. Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
Sun H; Liu SY; Zhou JY; Xu JT; Zhang HK; Yan HH; Huan JJ; Dai PP; Xu CR; Su J; Guan YF; Yi X; Yu RS; Zhong WZ; Wu YL
EBioMedicine; 2020 Oct; 60():102990. PubMed ID: 32927274
[TBL] [Abstract][Full Text] [Related]
17. Comparative profiling of single-cell transcriptome reveals heterogeneity of tumor microenvironment between solid and acinar lung adenocarcinoma.
Li D; Yu H; Hu J; Li S; Yan Y; Li S; Sun L; Jiang G; Hou L; Zhang L; Zhang P
J Transl Med; 2022 Sep; 20(1):423. PubMed ID: 36138435
[TBL] [Abstract][Full Text] [Related]
18. Necroptosis Identifies Novel Molecular Phenotypes and Influences Tumor Immune Microenvironment of Lung Adenocarcinoma.
Zhao C; Xiong K; Adam A; Ji Z; Li X
Front Immunol; 2022; 13():934494. PubMed ID: 35911707
[TBL] [Abstract][Full Text] [Related]
19. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
20. Integrative analysis reveals distinct subtypes with therapeutic implications in KRAS-mutant lung adenocarcinoma.
Liu K; Guo J; Liu K; Fan P; Zeng Y; Xu C; Zhong J; Li Q; Zhou Y
EBioMedicine; 2018 Oct; 36():196-208. PubMed ID: 30268834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
